Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K020185
    Manufacturer
    Date Cleared
    2002-02-06

    (19 days)

    Product Code
    Regulation Number
    866.1645
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    To determine antimicrobial agent susceptibility

    Device Description

    MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panels are designed for use in determining quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-negative bacilli. The MicroScan® rapID/S play® 40 growing actions and faculture and on the WalkAway SV System or equivalent (upgraded WalkAway® 40 or WalkAway® 96 instruments).

    The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test that have The allinited in Mueller-Hinton Broth to concentrations bridging the range of clinical interest and are presented in micro-titer wells in dried form. rapID/S plus™ panels are inoculated and rehydrated with a standardized suspension of the organism and incubated at 35℃ in the WalkAway® S/ System or equivalent standardized suspension of the organism and securition (MIC) for the test organism is determined by the lowest antimicrobial concentration showing inhibition of growth.

    AI/ML Overview

    The provided text describes the 510(k) summary for the MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panels with Gentamicin. Here's a breakdown of the requested information:

    1. Table of Acceptance Criteria and Reported Device Performance

    The text primarily focuses on the "Essential Agreement" metric, which is a common performance criterion for antimicrobial susceptibility devices. While specific numerical acceptance criteria (e.g., "should be > X%") are not explicitly stated, the reported performance is given.

    MetricAcceptance Criteria (Implied)Reported Device Performance
    Overall Essential Agreement (compared to NCCLS frozen Reference Panel)Undefined but implied to be high for acceptance.Greater than 96% for Gentamicin
    Reproducibility for Gentamicin (with Turbidity inoculum preparation and WalkAway® SI System)AcceptableAcceptable
    Quality Control testing for GentamicinAcceptableAcceptable

    2. Sample Size Used for the Test Set and Data Provenance

    The text states: "The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains." However, no specific sample size (number of isolates/strains) is provided for the test set.

    The data provenance is not explicitly stated in terms of country of origin. The study appears to be retrospective (using "fresh and stock isolates") rather than prospective, as it's an evaluation of an existing methodology against a reference.

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Experts

    This information is not provided in the document. The ground truth for the test set was established against an "NCCLS frozen Reference Panel" and "Expected Results" for Challenge strains, but the process of how these reference results were generated or by whom is not detailed.

    4. Adjudication Method for the Test Set

    This information is not provided in the document. The comparison was made against a "NCCLS frozen Reference Panel" and "Expected Results," implying a direct comparison without a separate adjudication process among multiple readers/evaluators of the device's results.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    No MRMC comparative effectiveness study is mentioned. The study described is a standalone performance evaluation against a reference standard. The device determines antimicrobial susceptibility automatically, so the concept of "human readers improve with AI vs without AI assistance" does not directly apply here.

    6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study

    Yes, a standalone study was performed. The described evaluation assesses the performance of the MicroScan® rapID/S plus™ Gram-Negative MIC/Combo Panel (the device itself) in determining antimicrobial susceptibility. The device interprets the results to determine the Minimum Inhibitory Concentration (MIC) for the test organism without human intervention during the reading process. The text states: "The MIC for the test organism is determined by the lowest antimicrobial concentration showing inhibition of growth."

    7. Type of Ground Truth Used

    The ground truth used was a reference standard. Specifically:

    • An NCCLS frozen Reference Panel was used for comparison of the rapID/S plus™ Gram-Negative Panel.
    • "Expected Results" were used for Challenge strains.

    8. Sample Size for the Training Set

    This information is not provided in the document. The text describes an evaluation study, but details about the development or training of the device's underlying algorithms (if any complex algorithms are involved beyond direct measurement) are not included.

    9. How the Ground Truth for the Training Set Was Established

    Since the sample size for the training set is not provided, and the document focuses on the evaluation, how the ground truth for any potential training set was established is not detailed.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1